GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zivo Bioscience Inc (OTCPK:ZIVO) » Definitions » ROC (Joel Greenblatt) %

ZIVO (Zivo Bioscience) ROC (Joel Greenblatt) % : -29,018.18% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Zivo Bioscience ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Zivo Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -29,018.18%.

The historical rank and industry rank for Zivo Bioscience's ROC (Joel Greenblatt) % or its related term are showing as below:

ZIVO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -37310.53   Med: -14755.44   Max: -5061.32
Current: -18354.4

During the past 13 years, Zivo Bioscience's highest ROC (Joel Greenblatt) % was -5061.32%. The lowest was -37310.53%. And the median was -14755.44%.

ZIVO's ROC (Joel Greenblatt) % is ranked worse than
95.08% of 1402 companies
in the Biotechnology industry
Industry Median: -310.545 vs ZIVO: -18354.40

Zivo Bioscience's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Zivo Bioscience ROC (Joel Greenblatt) % Historical Data

The historical data trend for Zivo Bioscience's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zivo Bioscience ROC (Joel Greenblatt) % Chart

Zivo Bioscience Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17,461.22 -22,428.95 -8,085.19 -5,061.32 -13,634.69

Zivo Bioscience Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6,898.18 -5,934.88 -53,967.21 -25,828.57 -29,018.18

Competitive Comparison of Zivo Bioscience's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Zivo Bioscience's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zivo Bioscience's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zivo Bioscience's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Zivo Bioscience's ROC (Joel Greenblatt) % falls into.


;
;

Zivo Bioscience ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.028 + 0 + 0.25) - (1.026 + 0.045 + 1.131)
=-1.924

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.002 + 0 + 0.091) - (0.807 + 0 + 1.097)
=-1.811

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Zivo Bioscience for the quarter that ended in Dec. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-6.384/( ( (0.022 + max(-1.924, 0)) + (0 + max(-1.811, 0)) )/ 1 )
=-6.384/( ( 0.022 + 0 )/ 1 )
=-6.384/0.022
=-29,018.18 %

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zivo Bioscience  (OTCPK:ZIVO) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Zivo Bioscience ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Zivo Bioscience's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zivo Bioscience Business Description

Traded in Other Exchanges
N/A
Address
2125 Butterfield Drive, Suite 100, Troy, MI, USA, 48084
Zivo Bioscience Inc is a research and development company operating in both the biotech and agtech sectors, with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company's candidates are Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Companion Animal Food Ingredient, NDI (New Dietary Ingredient, and Skin Health.
Executives
Mark E Strome 10 percent owner 100 WILSHIRE BLVD, 15TH FL, SANTA MONICA CA 90401
John Bernard Payne director 9900 NE 114TH CIRCLE, VANCOUVER WA 98662
Alison A Cornell director 210 CARNEGIE CENTER, PRINCETON NJ 08540
Christopher D. Maggiore officer: CHIEF FINANCIAL OFFICER 4788 NOBLES POND DR. NW, CANTON OH 44718
Nola E Masterson director 768 WEST CALIFORNIA WAY, WOODSIDE CA 94062
Strome Mezzanine Fund, Lp 10 percent owner 100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401
Keith Marchiando officer: Chief Financial Officer C/O ZIVO BIOSCIENCE, INC., 21 E. LONG LAKE ROAD, SUITE 100, BLOOMFIELD HILLS MI 48304
Strome Alpha Fund L P 10 percent owner 100 WILSHIRE BLVD SUITE 1750, SANTA MONICA CA 90401
Strome Investment Management Lp 10 percent owner 100 WILSHIRE BLVD, 15TH FLOOR, SANTA MONICA CA 90401
Strome Group, Inc. 10 percent owner 100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401
Hep Investments Llc 10 percent owner 2804 ORCHARD LAKE RD, STE 205, KEEGO HARBOR MI 48320
Rondeau Robert O Jr director 70 WEST LONG LAKE RD, STE 119, TROY MI 48098
Thomas Kevin Cox director 470 MICHGAMME LANE, LAKE FOREST IL 60045
Andrew A Dahl officer: President, CEO 7 WEST SQUARE LAKE ROAD, STE 6165, BLOOMFIELD HILLS MI 48302
Brian W Young other: See remarks below. 1800 NW CORPORATE BLVD, BOCA RATON FL 33431

Zivo Bioscience Headlines